Substance / Medication

Troleandomycin

Overview

Active Ingredient
troleandomycin
RxNorm CUI
10864

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Clinical Trials

365 trials linked to this intervention

365
Total Trials
43
Recruiting
119
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Trends of fluoroquinolones resistance in Mycoplasma and Ureaplasma urogenital isolates: Systematic review and meta-analysis.
Wu Yaping, Majidzadeh Nahal, Li Ying et al. · J Glob Antimicrob Resist · 2024
PMID: 38016593Meta-Analysis
Treatment of Mycoplasma genitalium infection in pregnancy: A systematic review of international guidelines.
Drew Richard J, Eogan Maeve · Int J Gynaecol Obstet · 2024
PMID: 38491782Meta-Analysis
Troleandomycin as an oral corticosteroid steroid sparing agent in stable asthma.
Evans D J, Cullinan P, Geddes D M · Cochrane Database Syst Rev · 2001
PMID: 11406054Meta-AnalysisFull text (PMC)
Disposition of tacrolimus in isolated perfused rat liver: influence of troleandomycin, cyclosporine, and gg918.
Wu Chi-Yuan, Benet Leslie Z · Drug Metab Dispos · 2003
PMID: 14570757Observational
Effects of macrolide antibiotics on CYP3A expression in human and rat hepatocytes: interspecies differences in response to troleandomycin.
Ledirac N, de Sousa G, Fontaine F et al. · Drug Metab Dispos · 2000
PMID: 11095572Observational
Liquid chromatography of troleandomycin.
Chepkwony H K, Roets E, Hoogmartens J · J Chromatogr A · 2001
PMID: 11358231Other
Drug-drug interactions and metabolism in cytochrome P450 2C knockout mice: application to troleandomycin and midazolam.
Grimsley Aidan, Gallagher Richard, Hutchison Michael et al. · Biochem Pharmacol · 2013
PMID: 23732297Preclinical
Inhibitory effect of troleandomycin on the metabolism of omeprazole is CYP2C19 genotype-dependent.
He Nan, Huang Song-Lin, Zhu Rong-Hua et al. · Xenobiotica · 2003
PMID: 12623762Trial

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Health Goals

Goals connected through associated conditions

Quick Facts

Type
Substance / Medication
Fully Specified Name
Troleandomycin (substance)
SNOMED CT
64130008
UMLS CUI
C0041165
RxNorm CUI
10864

Clinical Data

This intervention maps to 16 entities in the Healos knowledge graph.

10
Conditions
3
Biomarkers
2
Specialists
0
Symptoms
365
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.